The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas
Open accessAbstract
The molecular pathogenesis of pediatric astrocytomas is still poorly understood. To further understand the genetic abnormalities associated with these tumors, we performed a genome-wide analysis of DNA copy number aberrations in pediatric low-grade astrocytomas by using array-based comparative genomic hybridization. Duplication of the BRAF protooncogene was the most frequent genomic aberration, and tumors with BRAF duplication showed significantly increased mRNA levels of BRAF and a downstream target, CCND1, as compared with tumors without duplication. Furthermore, denaturing HPLC showed that activating BRAF mutations were detected in some of the tumors without BRAF duplication. Similarly, a marked proportion of low-grade astrocytomas from adult patients also had BRAF duplication. Both the stable silencing of BRAF through shRNA lentiviral transduction and pharmacological inhibition of MEK1/2, the immediate downstream phosphorylation target of BRAF, blocked the proliferation and arrested the growth of cultured tumor cells derived from low-grade gliomas. Our findings implicate aberrant activation of the MAPK pathway due to gene duplication or mutation of BRAF as a molecular mechanism of pathogenesis in low-grade astrocytomas and suggest inhibition of the MAPK pathway as a potential treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new mathematical model for relative quantification in real-time RT-PCR
Pfaffl, M. W. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.9.e45 · Cited by 34,610
A simple salting out procedure for extracting DNA from human nucleated cells
Miller, S. A., Dykes, D. D., & Polesky, H. F. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.3.1215 · Cited by 20,330
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Prevalence of ras gene mutations in human colorectal cancers
Bos, J. L., Fearon, E. R., Hamilton, S. R., Vries, M. V., van Boom, J. H., van der Eb, A. J., & Vogelstein, B. (1987) · Nature · doi:10.1038/327293a0 · Cited by 1,860
A Lentiviral RNAi Library for Human and Mouse Genes Applied to an Arrayed Viral High-Content Screen
Moffat, J., Grueneberg, D. A., Yang, X., Kim, S. Y., Kloepfer, A. M., Hinkle, G., Piqani, B., Eisenhaure, T. M., Luo, B., Grenier, J. K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.01.040 · Cited by 1,798
Kimura, E. T., Nikiforova, M. N., Zhu, Z., Knauf, J. A., Nikiforov, Y. E., & Fagin, J. A. (2003) · PubMed · Cited by 1,510
Ohgaki, H., & Kleihues, P. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.6.479 · Cited by 1,381
RAF/RAS oncogenes and mismatch-repair status
Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Nature · doi:10.1038/418934a · Cited by 1,224
Lichter, P., Cremer, T., Borden, J., Manuelidis, L., & Ward, D. C. (1988) · Human Genetics · doi:10.1007/bf01790090 · Cited by 1,160
Self-citationBRAF and RAS mutations in human lung cancer and melanoma.
Brose, M. S., Volpe, P., Feldman, M. D., Kumar, M. S., Rishi, I., Gerrero, R. M., Einhorn, E., Herlyn, M., Minna, J. D., Nicholson, A. G., et al. (2002) · PubMed · Cited by 1,048
Cited by
Recurrent BRAF mutations in Langerhans cell histiocytosis
Badalian-Very, G., Vergilio, J.-A., Degar, B. A., MacConaill, L. E., Brandner, B., Calicchio, M. L., Kuo, F. C., Ligon, A. H., Stevenson, K. E., Kehoe, S. M., et al. (2010) · Blood · doi:10.1182/blood-2010-04-279083 · Cited by 1,243
Weller, M., Wick, W., Aldape, K., Brada, M., Berger, M., Pfister, S. M., Nishikawa, R., Rosenthal, M., Wen, P. Y., Stupp, R., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.17 · Cited by 1,124
Self-citationSchindler, G., Capper, D., Meyer, J., Janzarik, W., Omran, H., Herold-Mende, C., Schmieder, K., Wesseling, P., Mawrin, C., Hasselblatt, M., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0802-6 · Cited by 1,034
Self-citationJones, D. T. W., Kocialkowski, S., Liu, L., Pearson, D. M., Bäcklund, L. M., Ichimura, K., & Collins, V. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2097 · Cited by 944
Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas
the St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2013) · Nature Genetics · doi:10.1038/ng.2611 · Cited by 835
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond
Holderfield, M., Deuker, M. M., McCormick, F., & McMahon, M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3760 · Cited by 833
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma
the International Cancer Genome Consortium PedBrain Tumor Project, Jones, D. T. W., Hutter, B., Jäger, N., Korshunov, A., Kool, M., Warnatz, H.-J., Zichner, T., Lambert, S. R., Ryzhova, M., et al. (2013) · Nature Genetics · doi:10.1038/ng.2682 · Cited by 825
Self-citationVemurafenib: the first drug approved for BRAF-mutant cancer
Bollag, G., Tsai, J., Zhang, J., Zhang, C., Ibrahim, P., Nolop, K., & Hirth, P. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3847 · Cited by 822
Medulloblastomics: the end of the beginning
Northcott, P. A., Jones, D. T. W., Kool, M., Robinson, G. W., Gilbertson, R. J., Cho, Y.-J., Pomeroy, S. L., Korshunov, A., Lichter, P., Taylor, M. D., et al. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3410 · Cited by 663
Self-citationOptic pathway gliomas in neurofibromatosis‐1: Controversies and recommendations
Listernick, R., Ferner, R. E., Liu, G. T., & Gutmann, D. H. (2007) · Annals of Neurology · doi:10.1002/ana.21107 · Cited by 576
Emerging insights into the molecular and cellular basis of glioblastoma
Dunn, G. P., Rinne, M. L., Wykosky, J., Genovese, G., Quayle, S. N., Dunn, I. F., Agarwalla, P. K., Chheda, M. G., Campos, B., Wang, A., et al. (2012) · Genes & Development · doi:10.1101/gad.187922.112 · Cited by 565
Declining childhood and adolescent cancer mortality
Smith, M. A., Altekruse, S. F., Adamson, P. C., Reaman, G. H., & Seibel, N. L. (2014) · Cancer · doi:10.1002/cncr.28748 · Cited by 542
Pilocytic astrocytoma: pathology, molecular mechanisms and markers
Collins, V. P., Jones, D. T. W., & Giannini, C. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1410-7 · Cited by 445
Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples
MacConaill, L. E., Campbell, C. D., Kehoe, S. M., Bass, A. J., Hatton, C., Niu, L., Davis, M., Yao, K., Hanna, M., Mondal, C., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007887 · Cited by 438
Pediatric low-grade glioma in the era of molecular diagnostics
Ryall, S., Tabori, U., & Hawkins, C. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00902-z · Cited by 351
Buckner, J. C., Brown, P. D., O'Neill, B. P., Meyer, F. B., Wetmore, C. J., & Uhm, J. H. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.10.1271 · Cited by 341
Dias-Santagata, D., Lam, Q., Vernovsky, K., Vena, N., Lennerz, J. K., Borger, D. R., Batchelor, T. T., Ligon, K. L., Iafrate, A. J., Ligon, A. H., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017948 · Cited by 315
Holzwarth, C., Vaegler, M., Gieseke, F., Pfister, S. M., Handgretinger, R., Kerst, G., & Müller, I. (2010) · BMC Cell Biology · doi:10.1186/1471-2121-11-11 · Cited by 314
Self-citationPollack, I. F., Agnihotri, S., & Broniscer, A. (2019) · Journal of Neurosurgery: Pediatrics · doi:10.3171/2018.10.peds18377 · Cited by 314
Architecture of autoinhibited and active BRAF–MEK1–14-3-3 complexes
Park, E., Rawson, S., Li, K., Kim, B.-W., Ficarro, S. B., Pino, G. G.-D., Sharif, H., Marto, J. A., Jeon, H., & Eck, M. J. (2019) · Nature · doi:10.1038/s41586-019-1660-y · Cited by 309
Forshew, T., Tatevossian, R. G., Lawson, A. R., Ma, J., Neale, G., Ogunkolade, B. W., Jones, T. A., Aarum, J., Dalton, J., Bailey, S., et al. (2009) · The Journal of Pathology · doi:10.1002/path.2558 · Cited by 304
Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations
Bouffet, E., Hansford, J. R., Garrè, M. L., Hara, J., Plant-Fox, A., Aerts, I., Locatelli, F., van der Lugt, J., Papusha, L., Sahm, F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303815 · Cited by 296
Microglia/Brain Macrophages as Central Drivers of Brain Tumor Pathobiology
Gutmann, D. H., & Kettenmann, H. (2019) · Neuron · doi:10.1016/j.neuron.2019.08.028 · Cited by 295
Raf kinases in cancer–roles and therapeutic opportunities
Maurer, G., Tarkowski, B., & Baccarini, M. (2011) · Oncogene · doi:10.1038/onc.2011.160 · Cited by 292
Mistry, M., Zhukova, N., Merico, D., Rakopoulos, P., Krishnatry, R., Shago, M., Stavropoulos, J., Alon, N., Pole, J. D., Ray, P. N., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3922 · Cited by 288
Self-citationSievert, A. J., & Fisher, M. J. (2009) · Journal of Child Neurology · doi:10.1177/0883073809342005 · Cited by 285
Molecular diagnostics of gliomas: state of the art
Riemenschneider, M. J., Jeuken, J. W. M., Wesseling, P., & Reifenberger, G. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0736-4 · Cited by 283
Self-citationKorshunov, A., Meyer, J., Capper, D., Christians, A., Remke, M., Witt, H., Pfister, S., von Deimling, A., & Hartmann, C. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0550-z · Cited by 279
Self-citationGnekow, A. K., Falkenstein, F., von Hornstein, S., Zwiener, I., Berkefeld, S., Bison, B., Warmuth-Metz, M., Driever, P. H., Soerensen, N., Kortmann, R.-D., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos202 · Cited by 279
Self-citationJohnson, A., Severson, E., Gay, L., Vergilio, J.-A., Elvin, J., Suh, J., Daniel, S., Covert, M., Frampton, G. M., Hsu, S., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0242 · Cited by 269
Huse, J. T., Snuderl, M., Jones, D. T. W., Brathwaite, C. D., Altman, N., Lavi, E., Saffery, R., Sexton-Oates, A., Blumcke, I., Capper, D., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1639-9 · Cited by 268
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer
Hrustanovic, G., Olivas, V., Pazarentzos, E., Tulpule, A., Asthana, S., Blakely, C. M., Okimoto, R. A., Lin, L., Neel, D. S., Sabnis, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3930 · Cited by 267
Frequent Gains at Chromosome 7q34 Involving BRAF in Pilocytic Astrocytoma
Bar, E. E., Lin, A., Tihan, T., Burger, P. C., & Eberhart, C. G. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181845622 · Cited by 261
Sievert, A. J., Jackson, E. M., Gai, X., Hakonarson, H., Judkins, A. R., Resnick, A. C., Sutton, L. N., Storm, P. B., Shaikh, T. H., & Biegel, J. A. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00225.x · Cited by 255
Long‐Term Epilepsy‐Associated Tumors
Thom, M., Blümcke, I., & Aronica, E. (2012) · Brain Pathology · doi:10.1111/j.1750-3639.2012.00582.x · Cited by 231
Fontebasso, A. M., Liu, X., Sturm, D., & Jabado, N. (2013) · Brain Pathology · doi:10.1111/bpa.12023 · Cited by 89
Buhl, J. L., Selt, F., Hielscher, T., Guiho, R., Ecker, J., Sahm, F., Ridinger, J., Riehl, D., Usta, D., Ismer, B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1965 · Cited by 84
Self-citationAllostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs
Nussinov, R., Zhang, M., Maloney, R., Liu, Y., Tsai, C.-J., & Jang, H. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167569 · Cited by 66
Metadata
- Authors
- Pfister, S., Janzarik, W. G., Remke, M., Ernst, A., Werft, W., Becker, N., Toedt, G., Wittmann, A., Kratz, C., Olbrich, H., Ahmadi, R., Thieme, B., Joos, S., Radlwimmer, B., Kulozik, A., Pietsch, T., Herold-Mende, C., Gnekow, A., Reifenberger, G., Korshunov, A., Scheurlen, W., Omran, H., & Lichter, P.
- Venue
- Journal of Clinical Investigation
- Published
- 2008-05-01
- Volume
- 118
- Issue
- 5
- Pages
- 1739-1749
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2126595521
- Cited by
- 523
- References
- 48
- FWCI
- 15.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.